Zamansky & Associates Announces Investigation of Genoptix, Inc. (GXDX)
26 Enero 2011 - 3:58PM
Business Wire
Zamansky & Associates (“Zamansky”) has commenced an
investigation into Genoptix, Inc. (NASDAQ: GXDX) to determine
whether the Company violated federal securities laws by making
false and misleading statements regarding its financial condition
and prospects.
On May 6, 2010, Genoptix announced its first quarter of 2010
financial results were far below consensus but nevertheless
maintained revenue and earnings guidance for 2010. Then, on June
16, 2010, Genoptix issued a press release providing a first look at
its second quarter of 2010 performance, and reducing its revenue
and earnings guidance for the full year. On this news, Genoptix’s
stock fell $5.69 per share to close at $17.19 per share on June 16,
2010, a drop of 25%.
What You May Do
If you have information that would assist Zamansky in its
investigation or would like to discuss your legal rights, you may,
without obligation or cost to you, e-mail jake@zamansky.com or call
(212) 742-1414. Zamansky also encourages anyone with information
regarding Genoptix’s conduct during the period from July 31, 2009
and June 15, 2010, to contact the Firm, including whistleblowers,
former employees, shareholders, and others.
About Zamansky & Associates
Zamansky & Associates is one of the leading law firms
specializing in securities fraud and financial services arbitration
and litigation. We represent both individual and institutional
investors. Our practice is nationally recognized for our unrivaled
ability to aggressively prosecute cases and recover losses.
To learn more about Zamansky, please visit our
website, www.zamansky.com.
Genoptix, Inc. (MM) (NASDAQ:GXDX)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Genoptix, Inc. (MM) (NASDAQ:GXDX)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
Real-Time news about Genoptix, Inc. (MM) (NASDAQ): 0 recent articles
Más de Zamansky & Associates, LLC Artículos de Noticias